Prostate Cancer | Proceedings from a CME Hybrid Symposium Series Held in Conjunction with the 2022 ASCO Annual Meeting

Featuring perspectives from Drs Andrew Armstrong, Alan Bryce and Alicia Morgans, including the following topics: Introduction (0:00) Case: A man in his early 70s with DIPSS low- to intermediate-risk post-essential thrombocythemia myelofibrosis (MF) — Warren S Brenner, MD (5:29) Case: A woman in her late 60s with primary MF who experiences disease progression after 3 years of ruxolitinib — Jeanne Palmer, MD (17:19) Case: A woman in her late 60s with disease progression after multiple regimens for post-polycythemia vera MF — Neil Morganstein, MD (30:51) A woman in her late 70s with post-PV MF with a JAK2 V617F mutation and transfusion dependence — Bhavana (Tina) Bhatnagar, DO (39:33) Case: A man in his mid 60s with primary MF with a JAK2 mutation and recurrent herpes zoster reactivation on ruxolitinib — Niyati A Nathwani, MD (50:23) Case: A man in his early 70s with prefibrotic primary MF with a JAK2 mutation and ruxolitinib-associated HPV reactivation — Susannah Friemel, MD (53:36) Case: A man in his early 20s with myeloproliferative neoplasm with a JAK2 V617F mutation and thrombocytosis — Rajni Sinha, MD, MRCP (57:16) CME information and select publications